Meeting
2015 ASCO Annual Meeting
Docetaxel + ramucirumab (DR) versus docetaxel + placebo (D) as second-line treatment for advanced non-small cell lung cancer (NSCLC): A randomized, phase II, double-blind, multicenter trial in Japan.
Authors
Yukio Hosomi
Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan
Yukio Hosomi , Kiyotaka Yoh , Kazuo Kasahara , Kazuhiko Yamada , Toshiaki Takahashi , Kaoru Tanaka , Toyoaki Hida , Hiroshige Yoshioka , Terufumi Kato , Koji Takeda , Makoto Nishio , Hiroshi Sakai , Makoto Maemondo , Mitsuhiro Takenoyama , Hiroshi Nokihara , Masumi Tatsumi , Takashi Nakamura , Sotaro Enatsu , Tomohide Tamura , Kazuhiko Nakagawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01703091
Citation
J Clin Oncol 33, 2015 (suppl; abstr 8054)
DOI
10.1200/jco.2015.33.15_suppl.8054
Abstract #
8054
Poster Bd #
377
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase II study of AK112 (PD-1/VEGF bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer.
First Author: Yuangyuan Zhao
Poster
2020 ASCO Virtual Scientific Program
Effect of anlotinib in advanced small cell lung cancer (SCLC) patients relapsed within three months after second-line treatment: A subgroup analysis from a randomized, double-blind phase II trial (ALTER 1202).
First Author: Jianhua Shi
Poster
2016 ASCO Annual Meeting
A phase II multicenter, randomized, placebo-controlled, double-blind study of CC-486 plus pembrolizumab (pembro) vs pembro plus placebo (PBO) in previously treated patients (pts) with locally advanced/metastatic non-small cell lung cancer (NSCLC).
First Author: Benjamin Philip Levy
Poster
2014 ASCO Annual Meeting
Phase II study of the AKT inhibitor MK-2206 plus erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who progressed on prior erlotinib: A California Cancer Consortium Phase II trial (NCI 8698).
First Author: Primo Lara Jr.